Merck and Moderna report Phase 3 results for intismeran autogene, plan 2027 launch

Merck and Moderna announced Phase 3 results for intismeran autogene, a personalized cancer vaccine used with Keytruda. In a study of over 1,100 melanoma patients, the combination reduced the risk of death or tumor recurrence by 42% and the risk of cancer spread by 38%. The companies plan to file for US regulatory approval and anticipate a potential product launch in 2027.

Detected & updated continuously · Source: Nebula